Abstract

To evaluate whether continuation rates with the 52-mg levonorgestrel-releasing intrauterine system (LNG-IUS) up to 5 years after placement differed between women using the method exclusively for contraception and those using the device for medical reasons alone. A retrospective cohort study was conducted in a family planning clinic with 5,034 LNG-IUS users: 4,287 using the method exclusively for contraception and 747 for medical reasons alone. The continuation rate at 1 to 5 years of use was calculated by life table analysis. Initially, the continuation rate was significantly higher in the contraception group: 85.8 versus 83.4 and 77.4 versus 76.0 per 100 women-years in the 1st and 2nd years of use, respectively. There were more discontinuations due to bleeding/spotting in the medical reasons group in the first two years. The discontinuation rate according to reason for use was not significantly different from the third to the fifth year of use. No women discontinued due to amenorrhea in either group. The continuation rate was significantly higher in the contraception group in the first two years of use. Amenorrhea was not a reason for discontinuation in either group, suggesting that counselling in this respect was adequate. Nevertheless, counselling could perhaps have been better with regards to the expected long period of bleeding and spotting in the first two years after placement.

Highlights

  • The 52-mg levonorgestrel-releasing intrauterine system (LNG-IUS) was developed by the Population Council’s International Committee for Contraception Research (ICCR) in the 1980s as a contraceptive method

  • Initially, the continuation rate was significantly higher in the contraception group: 85.8 versus 83.4 and 77.4 versus 76.0 per 100 women-years in the 1st and 2nd years of use, respectively

  • The continuation rate was significantly higher in the contraception group in the first two years of use

Read more

Summary

Introduction

The 52-mg levonorgestrel-releasing intrauterine system (LNG-IUS) was developed by the Population Council’s International Committee for Contraception Research (ICCR) in the 1980s as a contraceptive method. From the very beginning of its development, it was clear that the observed reduction in both the amount and duration of menstrual bleeding and the consequent improvement in hemoglobin levels constituted important non-contraceptive health benefits.[1,2] This finding led to subsequent approval of the method as a treatment for women with heavy menstrual bleeding (HMB).[3] The positive effect of this device in reducing pelvic pain in women with endometriosis, adenomyosis, and dysmenorrhea became evident a few years later and has been repeatedly confirmed.[4,5] Currently, the medical effects of the 52-mg LNG-IUS have become a major indication for its use, being as important as its role as a contraceptive. This side effect would be most welcome for women using the method to treat HMB or dysmenorrhea

Methods
Results
Discussion
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call